AAS
TNYA icon

Avantax Advisory Services’s Tenaya Therapeutics TNYA Stock Holding History

Avantax Advisory Services’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$23.5K Hold
38,500
– – ﹤0.01% 2340
2025
Q1 		$21.9K Buy
+38,500
New +$38K ﹤0.01% 2216

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Avantax Advisory Services's TNYA Position: Q2 2025 in Review

Avantax Advisory Services held its Tenaya Therapeutics (TNYA) position steady in Q2 2025 at 38,500 shares worth $23.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2340.

Avantax Advisory Services first reported a position in TNYA in Q1 2025 and has held it in 2 quarters since. 89 funds tracked by Wall St. Rank hold TNYA as of Q2 2025.

  • Avantax Advisory Services held 38,500 shares of Tenaya Therapeutics worth $23.5K as of Q2 2025.
  • Avantax Advisory Services left its Tenaya Therapeutics share count unchanged in Q2 2025.
  • Tenaya Therapeutics made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #2340 holding.
  • Avantax Advisory Services first reported a position in Tenaya Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 89 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.